| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Dimethoxycurcumin targets multiple pathways involved in cancer cell proliferation, inflammation, and oxidative stress. It inhibits the expression of cyclin-dependent kinase 4 (CDK4) and cyclin-D1 while inducing the expression of p53 and p21. The compound induces non-cytotoxic G2/M phase cell cycle arrest and apoptosis. Dimethoxycurcumin also activates Nrf2 in human HepG2 cells, and induces epigenetic changes and the expression of promoter methylated genes in leukemia cells. Its antiproliferative activity is mediated through cell cycle regulation and induction of apoptosis.
|
|---|---|
| ln Vitro |
In vitro, dimethoxycurcumin displays potent antiproliferative activity against human SKBR3 and MCF7 cancer cell lines with IC50 values of 955.0 nM and 1070.0 nM, respectively. It shows antimalarial activity against both chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum. The compound exhibits antitrypanosomal activity against various strains of Trypanosoma brucei brucei with EC50 values ranging from 450.0 nM to over 4000.0 nM. It also has antileishmanial activity against Leishmania major Friedlin promastigotes and Leishmania mexicana amastigotes with EC50 values of 2800.0 nM and 10000.0 nM, respectively. Dimethoxycurcumin activates Nrf2 in human HepG2 cells with a fold change of 35.7 and an EC50 of 16600.0 nM.
|
| ln Vivo |
In vivo, dimethoxycurcumin has demonstrated additive antitumor effects when combined with 5-fluorouracil in colon cancer models. The compound's metabolic stability compared to curcumin suggests improved in vivo bioavailability and efficacy. However, specific in vivo experimental details are limited in the available literature. The compound's anti-inflammatory and antioxidant activities have been observed in vivo, and it has been shown to inhibit mitogen-induced proliferation of CD4+ T cells, CD8+ T cells, and B cells in isolated human lymphocytes.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for dimethoxycurcumin are not typically performed because the compound's activity is assessed in cell-based assays. However, the compound's ability to activate Nrf2 can be assessed using cell-free transcription assays. Its antioxidant activity can be evaluated using cell-free assays such as DPPH radical scavenging or ABTS assays. The compound's ability to inhibit specific enzymes such as CDK4 could be evaluated using biochemical kinase assays with recombinant proteins.
|
| Cell Assay |
In vitro cellular assays for dimethoxycurcumin are performed using various cancer cell lines, including SKBR3, MCF7, and HCT116 cells. Cells are treated with varying concentrations of dimethoxycurcumin, and cell viability is measured using MTT assays. Cell cycle distribution is analyzed by flow cytometry to assess G2/M phase arrest. Apoptosis is evaluated using annexin V staining or caspase activity assays. The expression of CDK4, cyclin-D1, p53, and p21 is measured by Western blotting or quantitative PCR. Nrf2 activation is assessed by measuring the expression of Nrf2 target genes.
|
| Animal Protocol |
In vivo animal experiments for dimethoxycurcumin have been conducted in colon cancer models. Mice bearing HCT116 tumor xenografts are treated with dimethoxycurcumin alone or in combination with 5-fluorouracil via oral or intraperitoneal administration. Tumor growth inhibition is monitored, and endpoints include tumor volume, tumor weight, and survival. The compound's anti-inflammatory effects can be evaluated in models of immune activation, where lymphocyte proliferation and cytokine production are assessed.
|
| ADME/Pharmacokinetics |
Dimethoxycurcumin has a molecular weight of 396.43 g/mol and a molecular formula of C23H24O6. The compound is a yellow solid with a purity of ≥98%. It is soluble in DMSO and other organic solvents. Detailed pharmacokinetic properties such as bioavailability, half-life, and tissue distribution have not been extensively reported. However, as a metabolically more stable analog of curcumin, dimethoxycurcumin is expected to have improved pharmacokinetic properties compared to the parent compound, including better oral bioavailability and longer half-life.
|
| Toxicity/Toxicokinetics |
Dimethoxycurcumin has been evaluated in preclinical studies and has been reported to be well-tolerated at effective doses. The compound displays cytotoxicity against human HEK293 cells with an EC50 of 200000.0 nM and a selectivity index of 70.0 for Leishmania species. No significant toxicity has been reported at therapeutic doses. However, comprehensive toxicology studies would be necessary to fully assess its safety for clinical development. As a curcumin analog, dimethoxycurcumin is generally considered to have a favorable safety profile.
|
| References |
: Zhao H, Liu Q, Wang S, Dai F, Cheng X, Cheng X, Chen W, Zhang M, Chen D. In vitro additive antitumor effects of dimethoxycurcumin and 5-fluorouracil in colon cancer cells. Cancer Med. 2017 Jul;6(7):1698-1706. doi: 10.1002/cam4.1114. Epub 2017 Jun 2. PubMed PMID: 28573788; PubMed Central PMCID: PMC5504307.
|
| Additional Infomation |
Dimethoxycurcumin is a synthetic and metabolically more stable analog of curcumin that exhibits a 30-fold increase in potency against HCT116 tumor cells. It displays a range of bioactivities including antimalarial, antiproliferative, antitrypanosomal, antileishmanial, and antimycobacterial activities. The compound induces epigenetic changes in leukemia cells, inhibits CDK4 and cyclin-D1 expression, and induces p53 and p21 expression. Dimethoxycurcumin also activates Nrf2 and has anti-inflammatory and antioxidant activities. It is a research compound with potential applications in cancer and infectious diseases.
|
| Molecular Formula |
C23H24O6
|
|---|---|
| Molecular Weight |
396.43306
|
| Exact Mass |
396.157
|
| CAS # |
160096-59-3
|
| Related CAS # |
160096-59-3;
|
| PubChem CID |
9952605
|
| Appearance |
Yellow to brown solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
587.0±50.0 °C at 760 mmHg
|
| Flash Point |
254.4±30.2 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.585
|
| LogP |
4.11
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
29
|
| Complexity |
534
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=C(C=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)OC)OC)OC
|
| InChi Key |
HMJSBVCDPKODEX-NXZHAISVSA-N
|
| InChi Code |
InChI=1S/C23H24O6/c1-26-20-11-7-16(13-22(20)28-3)5-9-18(24)15-19(25)10-6-17-8-12-21(27-2)23(14-17)29-4/h5-14H,15H2,1-4H3/b9-5+,10-6+
|
| Chemical Name |
(1E,6E)-1,7-bis(3,4-dimethoxyphenyl)hepta-1,6-diene-3,5-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~252.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5225 mL | 12.6126 mL | 25.2251 mL | |
| 5 mM | 0.5045 mL | 2.5225 mL | 5.0450 mL | |
| 10 mM | 0.2523 mL | 1.2613 mL | 2.5225 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA